替爾泊肽用于成人阻塞性睡眠呼吸暫停伴肥胖治療的研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

程鈺 ¹ , 余志書 ¹ , 馬曉琳 ² , 龐燕 ³ ,  李凱 ¹

1. ;
2. ;
3. ;

Corresponding?author：

李凱, Email: 31963623@qq.com

Keywords：

DOI：

10.7507/1671-6205.202509035

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 程鈺, 余志書, 馬曉琳, 龐燕, 李凱. 替爾泊肽用于成人阻塞性睡眠呼吸暫停伴肥胖治療的研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2026, 25(6): 450-456. doi: 10.7507/1671-6205.202509035 Copy

1.
2.
3.
4.
5.
6.
7.
8.
9.	Malhotra A, Heilmann CR, Banerjee KK, et al. Weight reduction and the impact on apnea-hypopnea index: A systematic meta-analysis. Sleep Med. 2024, 121: 26-31.
10.	Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024, 391(13): 1193-1205.
11.	Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021, 12(1): 143-157.
12.
13.	國家藥品監督管理局[EB/OL]. (2025.07. 03)[2025.09. 05].https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20250703152233167.html.
14.
15.
16.
17.	Wang L. Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP. Drug Des Devel Ther. 2022, 16: 1547-1559.
18.
19.
20.
21.	Ji L, Jiang H, Bi Y, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025, 392(22): 2215-2225.
22.
23.
24.
25.
26.
27.	Wang F, Zou J, Xu H, et al. Effects of Chronic Intermittent Hypoxia and Chronic Sleep Fragmentation on Gut Microbiome, Serum Metabolome, Liver and Adipose Tissue Morphology. Front Endocrinol (Lausanne). 2022, 13: 820939.
28.	Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab, 2024, 15: 20420188231222367.
29.
30.	Wu JY, Chen CC, Ling Tu W, et al. Clinical Impact of Tirzepatide on Patients With OSA and Obesity. Chest. 2025, 168(3): 785-796.
31.
32.
33.	Papaetis GS. GLP-1 receptor agonists, SGLT-2 inhibitors, and obstructive sleep apnoea: can new allies face an old enemy? Arch Med Sci Atheroscler Dis, 2023, 8: e19-e34.
34.
35.
36.
37.
38.
39.
40.	Bardóczi A, Matics ZZ, Turan C, et al. Efficacy of incretin-based therapies in obesity-related obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev. 2025, 82: 102119.
41.
42.
43.
44.
45.
46.	Quddos F, Hubshman Z, Tegge A, et al. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Sci Rep. 2023, 13(1): 20998.
47.	Lin HT, Tsai YF, Liao PL, et al. Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity. JAMA Netw Open. 2025, 8(7): e2521016.
48.
49.
50.
51.
52.
53.
54.
55.	FDA Adverse Event Reporting System (FAERS) Public Dashboard - FDA Adverse Event Reporting System (FAERS) Public Dashboard \| 工作表 - Qlik Sense[EB/OL]. [2025.09. 05].
56.
57.
58.
59.
60.
61.

1.
2.
3.
4.
5.
6.
7.
8.
9. Malhotra A, Heilmann CR, Banerjee KK, et al. Weight reduction and the impact on apnea-hypopnea index: A systematic meta-analysis. Sleep Med. 2024, 121: 26-31.
10. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024, 391(13): 1193-1205.
11. Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021, 12(1): 143-157.
12.
13. 國家藥品監督管理局[EB/OL]. (2025.07. 03)[2025.09. 05].https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20250703152233167.html.
14.
15.
16.
17. Wang L. Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP. Drug Des Devel Ther. 2022, 16: 1547-1559.
18.
19.
20.
21. Ji L, Jiang H, Bi Y, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025, 392(22): 2215-2225.
22.
23.
24.
25.
26.
27. Wang F, Zou J, Xu H, et al. Effects of Chronic Intermittent Hypoxia and Chronic Sleep Fragmentation on Gut Microbiome, Serum Metabolome, Liver and Adipose Tissue Morphology. Front Endocrinol (Lausanne). 2022, 13: 820939.
28. Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab, 2024, 15: 20420188231222367.
29.
30. Wu JY, Chen CC, Ling Tu W, et al. Clinical Impact of Tirzepatide on Patients With OSA and Obesity. Chest. 2025, 168(3): 785-796.
31.
32.
33. Papaetis GS. GLP-1 receptor agonists, SGLT-2 inhibitors, and obstructive sleep apnoea: can new allies face an old enemy? Arch Med Sci Atheroscler Dis, 2023, 8: e19-e34.
34.
35.
36.
37.
38.
39.
40. Bardóczi A, Matics ZZ, Turan C, et al. Efficacy of incretin-based therapies in obesity-related obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev. 2025, 82: 102119.
41.
42.
43.
44.
45.
46. Quddos F, Hubshman Z, Tegge A, et al. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Sci Rep. 2023, 13(1): 20998.
47. Lin HT, Tsai YF, Liao PL, et al. Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity. JAMA Netw Open. 2025, 8(7): e2521016.
48.
49.
50.
51.
52.
53.
54.
55. FDA Adverse Event Reporting System (FAERS) Public Dashboard - FDA Adverse Event Reporting System (FAERS) Public Dashboard | 工作表 - Qlik Sense[EB/OL]. [2025.09. 05].
56.
57.
58.
59.
60.
61.

Previous Article
肺癌患者免疫檢查點抑制劑肺炎的研究進展
Next Article
銅綠假單胞菌膜囊泡在下呼吸道感染中的作用研究進展

Chinese Journal of Respiratory and Critical Care Medicine

替爾泊肽用于成人阻塞性睡眠呼吸暫停伴肥胖治療的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content